Atara Biotherapeutics, Inc. Cash Flow Statement
ATRA|2 years of annual SEC 10-K data (FY2024-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 2 fiscal years. All figures from audited SEC 10-K filings.
Atara Biotherapeutics, Inc. used $51M in operating cash flow and negative free cash flow of $51M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -73.54 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 |
|---|---|---|
| Net Income | $32.7M | -$276.1M |
| Depreciation & Amortization | $2.1M | $4.8M |
| Operating Cash Flow | -$50.9M | -$193.0M |
| Capital Expenditures | $0 | $1.2M |
| Free Cash Flow | -$50.9M | -$194.2M |
| FCF Margin | -42.2% | -2265.3% |